Intranasal desmopressin (Octim): a safe and efficacious treatment option for children with bleeding disorders.
Desmopressin (1-deamino-8-D-arginine vasopressin (DDAVP)) has been shown to be an effective treatment option when administered both intravenously [1,2] and subcutaneously [3] to children with inherited bleeding disorders. We demonstrate here, both the efficacy and acceptability of a new intranasal DDAVP preparation, providing a cost effective treatment with good outcomes for children with bleed disorders.
Khair
K
K
Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Trust, London, UK. khairk@gosh.nhs.uk
Baker
K
K
Mathias
M
M
Burgess
C
C
Liesner
R
R
D000281:Administration, Intranasal; D000293:Adolescent; D002648:Child; D015331:Cohort Studies; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy*; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006490:Hemostatics / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D016896:Treatment Outcome
D006490:Hemostatics; D003894:Deamino Arginine Vasopressin